Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 11,331 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Head and Neck Cancer
Interventions: paclitaxel; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 23
States / cities: Palo Alto, California • Stanford, California • Miami, Florida + 18 more

Conditions: Kidney Cancer
Interventions: girentuximab, placebo; Biological · Other
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 39
States / cities: Anchorage, Alaska • Los Angeles, California • San Francisco, California + 34 more

Conditions: Carotid Artery Disease
Interventions: -PRECISE Nitinol Stent System (5F, 5.5F and 6F), ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW); Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
Interventions: BBO-8520, Pembrolizumab, BBO-10203; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 23
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 19 more

Conditions: Respiratory Depression
Interventions: Capnostream Monitor; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Enrollment: 1,495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Bronchopulmonary Dysplasia
Interventions: GSNO; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 29 Days to 365 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Infant, Newborn, Infant, Moderate Preterm
Interventions: Weaning from an incubator at a lower weight (1600 grams), Weaning from an incubator at a higher weight (1800 grams); Procedure
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 29 Weeks to 34 Weeks
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Negative Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Medical Chart Review, Stress Management Therapy, Survey Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio • Columbus, Ohio

Conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions: Sigvotatug Vedotin, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 84
States / cities: Fullerton, California • Golden, Colorado • Grand Junction, Colorado + 56 more

Conditions: Restless Legs Syndrome
Interventions: GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg, GSK1838262 Placebo match; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 42
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: NX-5948; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 28
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more

Conditions: Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions: Radiation Therapy, Temozolomide, Veliparib; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 145
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more

Conditions: Prenatal Disorder
Interventions: Standard Care, Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Arteriovenous Fistula
Interventions: SRM003, Participating Site's standard practice; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 41 more

Conditions: Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-cell Chronic Lymphocytic Leukemia, B-cell Non Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Interventions: PBCAR20A, Fludarabine, Cyclophosphamide; Genetic · Drug
Lead sponsor: Precision BioSciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Duarte, California • Stanford, California • New York, New York + 2 more

Conditions: Septic Shock
Interventions: Early Vasopressors, Early Fluids; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 50
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 36 more

Conditions: Breast Cancer, Physical Activity
Interventions: Aerobic Training - Fixed Schedule, Resistance Training - Fixed Schedule, Walking program, Aerobic Training - Flexible Schedule, Resistance Training - Flexible Schedule, Successful Survivorship Health Education and Support Group, Flexible support groups; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Heart Failure
Interventions: Cholecalciferol; Dietary Supplement
Lead sponsor: Case Western Reserve University; Other
Eligibility: 50 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Single Ventricle Heart Disease
Interventions: Udenafil, Placebo; Drug
Lead sponsor: Mezzion Pharma Co. Ltd; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 32 more

Conditions: Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions: Topotecan Hydrochloride Liposomes, 3-Dimensional Conformal Radiation Therapy, Cisplatin; Drug · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 10
States / cities: Chicago, Illinois • Iowa City, Iowa • Columbia, Missouri + 5 more

Conditions: Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
Interventions: NKX101 - CAR NK cell therapy; Biological
Lead sponsor: Nkarta, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2039
U.S. locations: 8
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Physician's Choice medications; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Duarte, California • Atlanta, Georgia • Lexington, Kentucky + 6 more

Conditions: Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
Interventions: brentuximab vedotin, rituximab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more

Search by objective public record fields.

Paclitaxel in Treating Patients With Advanced Head and Neck Cancer

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY

Inhaled Treatment for Bronchopulmonary Dysplasia

Incubator Weaning of Moderately Preterm Infants

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors

A Trial of Vitamin D Therapy in Patients With Heart Failure

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma